Pramlintide regulatory status
Current status of Pramlintide in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of Pramlintide?
Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 30, 2026
- FDA and compounding
- FDA approved in March 2005 as Symlin, for type 1 and type 2 diabetes in patients using mealtime insulin who have not achieved glucose control. The manufacturer is discontinuing it: FDA's drug shortage database lists SymlinPen 60 and SymlinPen 120 as To Be Discontinued (updated October 27, 2025), and Drugs@FDA lists Symlin's marketing status as discontinued. No generic pramlintide is approved. Pramlintide is not on any FDA compounding bulks list and is not sold through peptide vendors in any meaningful way.
- WADA
- Not WADA prohibited
- Access path
- Symlin is being discontinued in the United States, and no generic is approved, so a new prescription may not be fillable. Ask an endocrinologist about alternatives.
- Not available through compounding pharmacies or telehealth peptide clinics.
Full Pramlintide page: evidence, dosing in the literature, and sources
How has the status of Pramlintide changed over time?
- FDA
FDA approves Symlin (pramlintide) as an adjunct to insulin
FDA approved pramlintide injection (Symlin), a synthetic amylin analog, for use with mealtime insulin in type 1 and type 2 diabetes.
Regulatory: FDA approvedSource: Drugs@FDA: Symlin (pramlintide) NDA 021332
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Pramlintide and the source of each dated event.
- [1]FDA prescribing information for Symlin (pramlintide acetate) injection, via DailyMedFDA, 2024
- [2]WADA Prohibited ListWADA, 2026
- [3]FDA Drug Shortages: pramlintide acetate injection, SymlinPen 60 and SymlinPen 120 listed as To Be Discontinued (updated October 27, 2025)FDA, 2025
- [4]Drugs@FDA: NDA 021332, Symlin (pramlintide acetate), marketing status discontinuedFDA